Literature DB >> 25280185

Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age.

Eeva Piitulainen1, Laura Cano Montero, Meltem Nystedt-Düzakin, Berend C Stoel, Tomas Sveger, Per Wollmer, Hanan A Tanash, Sandra Diaz.   

Abstract

Alpha-1-antitrypsin (AAT) deficiency is a genetic risk factor for pulmonary emphysema. In 1972-74 all 200,000 Swedish new-born infants were screened for AAT deficiency. The aim of the present study was to investigate whether the PiZZ and PiSZ individuals identified by this screening have signs of emphysema and the role of smoking in this, compared with a random sample of control subjects at 35 years of age. The study participants underwent complete pulmonary function tests (PFT) and CT densitometry. The fifteenth percentile density (PD15) and the relative area below -910 HU (RA-910) were analyzed. Fifty-four PiZZ, 21 PiSZ and 66 PiMM control subjects participated in the study. No significant differences were found in lung function between the never-smoking AAT-deficient and control subjects. The 16 PiZZ ever-smokers had significantly lower carbon monoxide transfer coefficient (KCO) than the 20 PiSZ never-smokers (p = 0.014) and the 44 PiMM never-smokers (p = 0.005). After correction for the CT derived lung volume, the PiZZ ever-smokers had significantly lower PD15 (p = 0.046) than the ever-smoking controls. We conclude that 35-year-old PiZZ and PiSZ never-smokers have normal lung function when compared with never-smoking control subjects. The differences in KCO and CT densitometric parameters between the PiZZ ever-smokers and the control subjects may indicate early signs of emphysema.

Entities:  

Keywords:  COPD; CT densitometry; alpha-1-antitrypsin deficiency; lung function

Mesh:

Year:  2014        PMID: 25280185     DOI: 10.3109/15412555.2014.922068

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  7 in total

Review 1.  Recent advancements in understanding the genetic involvement of alpha-1 antitrypsin deficiency associated lung disease: a look at future precision medicine approaches.

Authors:  Auyon J Ghosh; Brian D Hobbs
Journal:  Expert Rev Respir Med       Date:  2022-01-13       Impact factor: 3.772

Review 2.  Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype.

Authors:  Gerard N McElvaney; Robert A Sandhaus; Marc Miravitlles; Gerard M Turino; Niels Seersholm; Marion Wencker; Robert A Stockley
Journal:  Eur Respir J       Date:  2020-06-18       Impact factor: 16.671

3.  Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency.

Authors:  Behrouz Mostafavi; Sandra Diaz; Eeva Piitulainen; Berend C Stoel; Per Wollmer; Hanan A Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-11-08

Review 4.  Advances in managing COPD related to α1 -antitrypsin deficiency: An under-recognized genetic disorder.

Authors:  Timothy J Craig; Maria Paula Henao
Journal:  Allergy       Date:  2018-07-26       Impact factor: 13.146

Review 5.  Update on α1-antitrypsin deficiency.

Authors:  Ilaria Ferrarotti; Stefania Ottaviani; Annalisa De Silvestri; Angelo G Corsico
Journal:  Breathe (Sheff)       Date:  2018-06

6.  Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years.

Authors:  Behrouz Mostafavi; Eeva Piitulainen; Hanan A Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-02-28

7.  Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42.

Authors:  Georg Rüdiger Schramm; Behrouz Mostafavi; Eeva Piitulainen; Per Wollmer; Hanan A Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-12-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.